Cox J H, Ivanyi J, Young D B, Lamb J R, Syred A D, Francis M J
MRC Tuberculosis and Related Infections Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Eur J Immunol. 1988 Dec;18(12):2015-9. doi: 10.1002/eji.1830181222.
The immunogenicity of synthetic peptide dimers based on epitope sequences derived from the mycobacterial 65-kDa antigen and the foot and mouth disease virus (FMDV) VP1 protein was examined in inbred mice. The analysis was directed towards the potential helper role of a T cell stimulatory mycobacterial epitope (65-85) with respect to poorly immunogenic sites either from the same molecule (422-436) or from VP1 (141-160). The 65-85 repeat homodimer induced an antibody response in CBA/ca but not in C57BL/6 mice, both nonresponders to the 65-85 monomer, and amplified the antibody response in BALB/c, monomer-responder mice. Analysis of the immunogenicity of hybrid dimers in BALB/c mice showed that the orientation of peptides within the dimer is critical for the extent of the produced antibody response. Only the 422-436/65-85 but not the 65-85/422-436 induced antibodies binding to the 422-436 sequence which was nonimmunogenic when injected either as a monomer or dimer. Despite the striking difference in immunogenicity, both tested hybrid dimers reacted equally in the solid-phase immunoassay with antisera raised to 65-85-dimer or 422-436/65-85 peptides or with a monoclonal antibody to the 422-436 epitope. The described differences in antibody responsiveness also cannot be attributed merely to the extent of T cell stimulation since the proliferative responses were uniformly expressed for all relevant combinations of peptides. Antisera to 65-85 dimer and 422-436/65-85 hybrid also reacted with the native 65-kDa protein. Furthermore, the production of FMDV-neutralizing antibodies in response to the 141-160 (VP1-derived)/65-85 hybrid peptide in 141-160 nonresponder B10.D2 mice also confirmed the helper activity of the 65-85 epitope. Thus, combining heterologous peptides with the N-terminal of the mycobacterial 65-85 sequence may be generally applicable for the potentiation of peptide vaccines.
在近交系小鼠中检测了基于源自分枝杆菌65-kDa抗原和口蹄疫病毒(FMDV)VP1蛋白的表位序列的合成肽二聚体的免疫原性。分析针对T细胞刺激分枝杆菌表位(65-85)对来自同一分子(422-436)或VP1(141-160)的免疫原性较差位点的潜在辅助作用。65-85重复同型二聚体在CBA/ca小鼠中诱导了抗体反应,但在C57BL/6小鼠中未诱导,这两种小鼠对65-85单体均无反应,并且在BALB/c(单体反应性小鼠)中增强了抗体反应。对BALB/c小鼠中杂合二聚体免疫原性的分析表明,二聚体内肽的方向对于所产生抗体反应的程度至关重要。只有422-436/65-85而非65-85/422-436诱导了与422-436序列结合的抗体,该序列以单体或二聚体形式注射时无免疫原性。尽管免疫原性存在显著差异,但两种测试的杂合二聚体在固相免疫测定中与针对65-85二聚体或422-436/65-85肽产生的抗血清或与针对422-436表位的单克隆抗体反应相同。所描述的抗体反应性差异也不能仅仅归因于T细胞刺激的程度,因为所有相关肽组合的增殖反应均一致表达。针对65-85二聚体和422-436/65-85杂合体的抗血清也与天然65-kDa蛋白反应。此外,在141-160无反应的B10.D2小鼠中,针对141-160(源自VP1)/65-85杂合肽产生口蹄疫病毒中和抗体也证实了65-85表位的辅助活性。因此,将异源肽与分枝杆菌65-85序列的N端结合可能普遍适用于增强肽疫苗。